Weekender: Biogen stocks up on Sage's brain drugs in $3B deal

Signup | Forward Weekender Nov.​ 28,​ 2020 | A roundup of this week's most read stories

BROUGHT TO YOU BY — CoverMyMeds Overcoming Medication Access Barriers Leverage technology to help patients overcome medication access barriers, from prior authorization to cost, and help them get on therapy sooner. Learn how.   {if length(top_stories)} {first=top_stories[0]} {if first.vars.sailthru_post_type == "Opinion"} {strip_tags(first.vars.sailthru_post_type)} {else if first.vars.sailthru_post_type != "Brief" && first.vars.sailthru_post_type != "Article" && first.vars.sailthru_post_type != None } {if first.vars.sailthru_post_type == "Podcast"} {/if} {strip_tags(first.vars.sailthru_post_type)} {/if} {{first.title}} {strip_tags(first.description)} {top_stories_last_index=length(top_stories) - 2} {foreach slice(top_stories,1) as i, c} {if i == 2} Sponsored Content by Guidehouse A pathway to competitiveness through innovation for specialty and generic companies Find out how the 505(b)(2) pathway may offer an attractive alternative for companies looking to differentiate their products and diversify their portfolios. Get the article. {/if} Regeneron COVID-19 drug, used to treat Trump, cleared for emergency use The drug is the second antibody-based treatment to win FDA emergency authorization this month, though supplies of both are very limited. {/foreach} {/if} {if length(recommended_for_you)} Recommended For You Improve your recommendations: click here to update your profile. {first=recommended_for_you[0]} {if first.vars.sailthru_post_type == "Opinion"} {strip_tags(first.vars.sailthru_post_type)} {else if first.vars.sailthru_post_type != "Brief" && first.vars.sailthru_post_type != "Article" && first.vars.sailthru_post_type != None } {if first.vars.sailthru_post_type == "Podcast"} {/if} {strip_tags(first.vars.sailthru_post_type)} {/if} {{first.title}} {strip_tags(first.description)} {recommended_for_you_last_index=length(recommended_for_you) - 2} {foreach slice(recommended_for_you,1) as i, c} {if i == 2} Sponsored Content by Guidehouse A pathway to competitiveness through innovation for specialty and generic companies Find out how the 505(b)(2) pathway may offer an attractive alternative for companies looking to differentiate their products and diversify their portfolios. Get the article. {/if} Regeneron COVID-19 drug, used to treat Trump, cleared for emergency use The drug is the second antibody-based treatment to win FDA emergency authorization this month, though supplies of both are very limited. {/foreach} {/if} Featured Resources FROM: Regulatory Affairs Professionals Society Strengthen Your Regulatory Knowledge Grow your knowledge with RAPS Regulatory Affairs Certificate in Pharmaceuticals Stay up-to-date with the newly-updated Chemistry, Manufacturing and Controls online course Advance your strategy with the freshly revamped online course, Global Regulatory Strategy for Pharmaceuticals From Our Library Trendline Trends and developments in real-world evidence Playbook Reimagining Scientific Communications By studioID View all resources Best of What We're Reading STAT VC raises $800M for company aiming to transform biotech manufacturing Bloomberg Astra Vaccine's 90% Efficacy in Covid Came in Younger Group San Francisco Business Times Peninsula company wins first FDA OK for aging disease progeria Associated Press OxyContin maker Purdue Pharma pleads guilty in criminal case The Wall Street Journal Russia Looks to Undercut Rivals With Cut-Price Covid-19 Vaccine Reuters Dosing error turns into lucky punch for AstraZeneca and Oxford Suggest a story we should read Upcoming Events Accelerating Targeted Therapies: Defining the Signaling Pathways of Each Single Cell Dec. 2, 2020 - Dec. 2, 2020 | Webinar 2pm ET Taking the First Step Toward a Critical Evolution of Pharma’s Commercial Model Dec. 9, 2020 - Dec. 9, 2020 | Webinar 11am ET Dive Into a Topic Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy Share BioPharma Dive: Daily Dive with others and get rewarded. You've referred 0 readers. To become an official Dive Insider, just successfully refer 10 contacts to BioPharma Dive: Daily Dive. Here's your link to share: https://www.biopharmadive.com/signup/insiders/?signup_referred_by=5f93078d7aa51972095c9316

More Than A Newsletter Related Publications Healthcare Dive | MedTech Dive Connect With Us Twitter | LinkedIn Editorial Contact an editor | Meet the team Advertising Contact our team About BioPharma Dive BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries. Sign up for the newsletter This email is optimized for display on mobile phones. BioPharma Dive: Daily Dive is a product of Industry Dive, Inc.. 1575​ Eye St NW, 4th Floor, Washington,​ DC 20005. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe or switch to a weekly newsletter subscription anytime. See our full privacy policy.

Sign up | Manage subscription | Advertise with us | Submit story tip